Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Dose-escalation and Expansion, First-in-human Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JBZ-001, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Patients With Advanced Solid and Hematological Malignancies

Next Previous
Trial Profile

A Phase 1, Open-label, Dose-escalation and Expansion, First-in-human Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JBZ-001, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Patients With Advanced Solid and Hematological Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JBZ 001 (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Jabez Biosciences

Most Recent Events

  • 15 Aug 2025 According to Jabez Biosciences media release, announced the opening of a second clinical site for this trial.The Phase 1 study is now enrolling patients at a second site, START Mountain Region in West Valley City, UT, under the direction of William McKean, MD, PhD. The study initially opened in March 2025 and continues to enroll at The Ohio State University Comprehensive Cancer Center.
  • 30 Apr 2025 Clinical trial design presented at the 116th Annual Meeting of the American Association for Cancer Research.
  • 12 Mar 2025 Planned initiation date changed from 15 Feb 2025 to 30 Mar 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top